Exogenous progesterone for cannabis withdrawal in women: Feasibility trial of a novel multimodal methodology.
Pharmacol Biochem Behav
; 179: 22-26, 2019 04.
Article
em En
| MEDLINE
| ID: mdl-30711528
ABSTRACT
BACKGROUND:
Sex differences in cannabis use disorder (CUD) and its treatment have been identified. Women report more severe withdrawal and have shown worse treatment outcomes. Ovarian hormones are implicated in these differences and research suggests that exogenous progesterone may be an effective pharmacotherapy.METHODS:
The current randomized, placebo-controlled, feasibility trial tested a novel multimodal methodology for administering exogenous progesterone during acute cannabis withdrawal. Eight heavy cannabis using women received micronized progesterone (200â¯mg bid) (nâ¯=â¯3) or matching placebo (nâ¯=â¯5) during the early follicular phase of their menstrual cycle over a 5-day study period while abstaining from cannabis. Laboratory visits (days 1 and 5) included biological and self-report assessments, while home-based procedures (days 2-4) included ambulatory assessments, video data capture and tele-drug testing, and biological assessments. Primary outcomes were medication adherence and salivary hormone levels, and the exploratory outcome was cannabis withdrawal severity.RESULTS:
Medication adherence rates were high as assessed via self-report (100.0%) and video data capture (98.0%). Salivary progesterone levels differed between groups over time (pâ¯<â¯0.027) and the progesterone group achieved levels within the normal range during the luteal phase in healthy adults. All tele-drug tests were negative confirming cannabis abstinence and there was an indication (pâ¯=â¯0.07) of reduced cannabis craving among participants receiving progesterone.CONCLUSION:
More effective and sex-based treatments for cannabis use disorder are needed. The current study provides a novel multimodal methodology with low participant burden for investigating new medications for cannabis withdrawal. Clinical trials of progesterone for cannabis withdrawal may be warranted.
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
Base de dados:
MEDLINE
Assunto principal:
Progesterona
/
Síndrome de Abstinência a Substâncias
/
Cannabis
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Pharmacol Biochem Behav
Ano de publicação:
2019
Tipo de documento:
Article